Safety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials
Amin, Hamza Muhammad Hasan, Sundas Abukhater, Reem Lilley, Rachel Atique, Arif Shoaib, Maheen Sattar Albustanji, Qutaiba Sadique, Humza Khalid, Saad Muhammad Hasan, Ali
Amin, Hamza Muhammad
Hasan, Sundas
Abukhater, Reem
Lilley, Rachel
Atique, Arif
Shoaib, Maheen Sattar
Albustanji, Qutaiba
Sadique, Humza
Khalid, Saad Muhammad
Hasan, Ali
Abstract
Background and objective: Targeting the interleukin-23 (IL-23) pathway is an emerging therapeutic strategy for moderate to severe ulcerative colitis (UC). This systematic review and meta-analysis evaluated the efficacy and safety of IL-23 inhibitors for induction and maintenance therapy in UC.
Methods: A systematic search of PubMed, Cochrane, and Google Scholar was conducted up to May 2025 to identify randomized controlled trials (RCTs) of IL-23 inhibitors (mirikizumab, risankizumab, guselkumab) in UC. Data were analyzed using Review Manager (RevMan 5.4) with a random-effects model.
Results: Seven RCTs (four induction, three maintenance) including 4203 patients were analyzed. IL-23 inhibitors significantly increased clinical remission during both induction (RR 1.52) and maintenance (RR 1.62). Rates of histo-endoscopic healing were also higher with IL-23 blockade in both induction (RR 2.53) and maintenance (RR 1.81). Importantly, IL-23 inhibitors were associated with a reduced risk of serious adverse events during induction (RR 0.39), with no significant difference observed during maintenance (RR 0.68). Other outcomes, including clinical response and corticosteroid-free remission, also consistently favored IL-23 blockade.
Conclusion: IL-23 inhibitors provide significant improvements in clinical remission and mucosal healing, with a favorable safety profile, particularly during induction therapy in moderate to severe UC.
MIDER Authors
Date
2025-12-30
Type
Article
Subject
Colitis, Ulcerative, Drug Therapy
Collections
Citation
Amin HM, Hasan S, Abukhater R, Lilley R, Atique A, Shoaib MS, Albustanji Q, Sadique H, Khalid SM, Hasan A, Majeed S, Shahzad MA, Shahzad M, Ahmed M, Ahmed R, Gardezi SA. Safety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Int J Colorectal Dis. 2025 Dec 30;41(1):1. doi: 10.1007/s00384-025-05014-5.
Journal / Source Title
International Journal of Colorectal Disease
DOI
10.1007/s00384-025-05014-5
PMID
41467943
Publisher
Springer
Publisher’s URL
https://pmc.ncbi.nlm.nih.gov/articles/PMC12764650/
Publisher’s statement
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.